CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Amazon Explores AI Content Marketplace With Media Publishers 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
(4) - EconoTimes)
SOUTH SAN FRANCISCO, Calif., April 09, 2018 -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported the grant of inducement awards to its Senior Vice President and General Counsel, Mina Kim, effective as of April 9, 2018. Ms. Kim has nearly 20 years of corporate legal experience, most recently as the General Counsel of the publicly listed companies Sunrun Inc. and Fly Leasing Limited.
The compensation committee of Atara's board of directors granted Ms. Kim a stock option to purchase 70,000 shares of Atara’s common stock, and restricted stock units to acquire 42,500 shares of Atara’s common stock. The stock option and restricted stock units were granted as an inducement material to Ms. Kim entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option has a seven-year term and an exercise price of $36.00, equal to the per share closing price of Atara's common stock as reported by Nasdaq on April 9, 2018. The awards vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting over the following three years, assuming the employee is continuously employed by Atara as of such vesting dates.
Atara is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a leading T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. The Company's off-the-shelf, or allogeneic, T-cells are bioengineered from donors with healthy immune function and allow for rapid delivery from inventory to patients without a requirement for pretreatment. Atara's T-cell immunotherapies are designed to precisely recognize and eliminate cancerous or diseased cells without affecting normal, healthy cells.
INVESTOR & MEDIA CONTACTS:
Investors:
John Craighead, Atara Biotherapeutics
650-491-5806
[email protected]
Steve Klass, Burns McClellan
212-213-0006 x331
[email protected]
Media:
Justin Jackson, Burns McClellan
212-213-0006 x327
[email protected]
